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CASE REPORT Open Access
Case report: a thiazide diuretic to
treat polyuria induced by tolvaptan
Bart J. Kramers* , Maatje D. A. van Gastel, Esther Meijer and Ron T. Gansevoort
Abstract
Background: Currently, the vasopressin V2 receptor antagonist tolvaptan is the only available treatment for
autosomal dominant polycystic kidney disease (ADPKD), but there are tolerability issues due to aquaretic side-
effects such as polyuria. A possible strategy to ameliorate these side-effects may be addition of a thiazide diuretic,
this is an established treatment in nephrogenic diabetes insipidus, a condition where vasopressin V2 receptor
function is absent.
Case presentation: We describe a 46-year-old male ADPKD-patient, who was prescribed tolvaptan, which caused
polyuria of around 5 l per day. Hydrochlorothiazide was added to treat hypertension, which resulted in a marked
decrease in urine production. While using tolvaptan, rate of eGFR decline was − 1.35 mL/min/1.73m2 per year,
whereas after hydrochlorothiazide was initiated this was − 3.97 mL/minute/1.73m2 per year.
Conclusions: This case report indicates that while addition of hydrochlorothiazide may improve tolerability of
vasopressin V2 receptor antagonists, co-prescription should only be used with great scrutiny as it may decrease
tolvaptan effect on rate of ADPKD disease progression.
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Background
Autosomal dominant polycystic kidney disease (ADPKD)
is characterized by the formation of numerous cysts in
both kidneys, leading to renal function loss, with eventu-
ally need for renal replacement therapy in the majority
of patients [1]. ADPKD is the most common hereditary
renal disease and occurs in 3 to 4 per 10,000 people in
the general population [2], accounting for 10% of all
patients receiving renal replacement therapy [3].
Tolvaptan, a vasopressin V2 receptor antagonist, has
recently been registered as the first treatment for
ADPKD in Europe, Japan and Canada. In the TEMPO
3:4 trial, performed in ADPKD patients with relatively
preserved kidney function and large kidneys, tolvaptan
slowed the annual rate of renal function decline by 26%
from − 3.70 to − 2.72 mL/min/1.73m2 when compared
to placebo [4]. Recently, the REPRISE trial demonstrated
tolvaptan efficacy in later-stage ADPKD [5]. Being a
vasopressin V2 receptor antagonist, tolvaptan causes
aquaretic side-effects, such as polyuria (6.0 ± 1.8 l per
day), thirst, nocturia and polydipsia [4, 6]. These
side-effects impact quality of life and were the main
reason for tolvaptan discontinuation in the major trials.
Additional treatment to reduce polyuria may be an op-
tion to improve tolvaptan tolerability. Since the polyuria
is caused by a pharmacological blockade of the vasopres-
sin V2 receptor, it is of interest to study drugs that are
known to effectively reduce polyuria in a situation when
vasopressin V2 receptor function is absent, such as in
patients with nephrogenic diabetes insipidus. In such
patients hydrochlorothiazide (HCT) is known to reduce
polyuria by up to 50% [7–9].
The Summary of Medicinal Products Characteristics
of tolvaptan cautions that HCT is relatively contraindi-
cated during tolvaptan use, because of the theoretical
risk that concomitant use of tolvaptan (an aquaretic)
and HCT (a diuretic, or better a saluretic), may cause
severe dehydration [10].
In our center, 33 patients started tolvaptan treatment
as part of the TEMPO 3:4 trial [4]. We report data on
one of these patients, who received HCT despite the
aforementioned relative contraindication, as treatment
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for difficult-to-manage hypertension. This thiazide diur-
etic influenced his urinary volume notably.
Case presentation
A 46-year-old Caucasian male was assigned to tolvaptan
treatment as part of the TEMPO 3:4 trial in 2008.
ADPKD had been diagnosed by ultrasound in 1998,
which was performed because of hypertension and a
positive family history for ADPKD. DNA analysis later
showed a PKD2 mutation. In 2008, serum creatinine
level was 94 μmol/L, with an eGFR of 83 mL/min/
1.73m2 as calculated by the CKD-EPI formula [11]. Total
kidney volume (TKV) was 2351 mL, and height adjusted
TKV 1292 mL/m, corresponding to MAYO risk class 1D
[12]. Urine showed microalbuminuria (albumin: creatin-
ine ratio 4.75 g/mmol). Pre-tolvaptan, his 24-h urine
volume was 1300 mL.
In that same year, tolvaptan was initiated and
uptitrated to the maximum dose of 120 mg per day
(90/30 mg) within three weeks. After completion of
the TEMPO 3:4 trial, tolvaptan was stopped for one
month. Thereafter tolvaptan was re-started as part of
a compassionate use program. In 2015 this patient
developed hypertension despite use of an angiotensin
II receptor blocker (losartan 100 mg q.d.) and a
beta-blocker (metoprolol 100 mg b.i.d.). Previously an
alpha-blocker and a calcium antagonist had led to in-
tolerable side-effects. Therefore HCT was started at a
dose of 12.5 mg q.d. that was well-tolerated, and was
later increased to 25 mg q.d.
Urinary volumes before and during tolvaptan treat-
ment are shown in Fig. 1. In 2011, this patient collected
24-h urine once during the month in which tolvaptan
was temporarily stopped. At that time urine volume was
1280 mL and urine osmolality 632 mOsm/kg. Mean
24-h urine volume (based on five measurements) on
tolvaptan before HCT initiation was 4867 mL, mean
urine osmolality was 212 mOsm/kg (range 164–
250 mOsm/kg). After initiation of HCT (12.5 mg q.d.)
24-h urine production declined to 2878 mL, while urine
osmolality increased to 290 mOsm/kg. After the increase
of HCT to 25 mg q.d. the last 24-h urine collection mea-
sured 2699 mL and 280 mOsm/kg. Mean 24-h urine vol-
ume had declined during HCT co-treatment by 2078 mL
(43%).
24-h creatinine excretion was used to verify whether
urine collections were complete, assuming unchanged
muscle mass over time creatinine excretion should be
similar between urine collections. Mean 24-h creatinine
excretion before start of HCT was 18.1 mmol/24 h, and
after start of HCT 16.7 mmol/24 h, indicating no differ-
ence in urine collected.
During the nine-year treatment period, serum elec-
trolytes were measured 37 times and stayed within
the normal range during the whole period. These
electrolytes include potassium (range 3.9–4.6 mmol/L),
sodium (range 136–144 mmol/L) and calcium (range
2.34–2.57 mmol/L). There were no differences in average
electrolyte concentration between the period with tolvap-
tan monotherapy and the period with tolvaptan-HCT
combination therapy.
eGFR declined from 83 mL/min/1.73m2 in 2008 to
57 mL/min/1.73m2 in 2017 (Fig. 2). While on tolvaptan
monotherapy the slope of eGFR decline was − 1.35 mL/
min/1.73m2 per year, whereas this was − 3.97 mL/minute/
1.73m2 per year while on tolvaptan-HCT combination
therapy.
Copeptin, a surrogate marker of vasopressin [13],
was measured a total of five times, all in a fasting
state around the same time in the morning. In the
three years on tolvaptan monotherapy it was mea-
sured twice, with values of 24.4 and 20.5 pmol/L. In
the month the patient temporarily stopped using tol-
vaptan, copeptin dropped to 11.1 pmol/L. Thereafter,
Fig. 1 24-h urine volume over time. Urine production increased notably after initiation (in 2008) and re-initiation (in 2011) of tolvaptan. After
hydrochlorothiazide (HCT) was added to tolvaptan treatment in 2015, urine volume decreased by 43%
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tolvaptan was reinitiated and copeptin increased to
23.3 pmol/L. Copeptin was highest during tolvaptan-HCT
combination therapy: 29.7 pmol/L.
Discussion
HCT has been an established treatment for polyuria in
nephrogenic diabetes insipidus for over 50 years [7] and
is known to lower urine output by up to 50% within
2–4 days [7–9]. The mechanism explaining this
paradoxical antidiuretic effect has never been fully
elucidated. Historically, the most widely accepted
theory is that HCT blocks the NaCl-cotransporter in
the distal convoluted tubule, leading to diminished
sodium reabsorption, and as a result extracellular
volume contraction, as well as an acute decrease in
GFR [14, 15]. Consequently, more sodium and water
are reabsorbed in the proximal tubule, less fluid is
delivered to the collecting duct, and total urine vol-
ume is decreased.
When HCT was started during tolvaptan use, no
side-effects were reported by our patient, nor were there
any electrolyte abnormalities or signs of dehydration
noted. Some clues as to what possible side-effects of
tolvaptan-HCT combination treatment may be on rate
of ADPKD progression can be derived from the copeptin
levels that we measured as surrogate for plasma
vasopressin levels [13]. An increase in level of agonist
(vasopressin), while remaining on the same dose of
antagonist (tolvaptan), could hypothetically attenuate the
effect of tolvaptan in slowing eGFR decline. In our
patient, copeptin level rose from 22.7 on tolvaptan
monotherapy, to 29.7 pmol/L (single measurement) on
tolvaptan-HCT therapy, suggesting that HCT caused an
increase in plasma copeptin. An increase in copeptin is
in accordance with the traditional view that HCT causes
a decrease in extracellular volume, which leads to a rise
in vasopressin. The evidence for this view however, is
limited. The scarce available data that show increased
vasopressin activity in patients using HCT was collected
in severely hyponatremic patients who received high
doses of HCT (mostly ≥100 mg) [16, 17]. In contrast,
one could argue that in patients with lower doses of
HCT and less hypovolemia, vasopressin could also be
suppressed in response to decreased plasma osmolality
caused by increased saluresis [18].
Increased copeptin levels could be unfavorable, as
upregulation of the vasopressin pathway in ADPKD is
associated with more rapid disease progression [19]. In
our one patient, there is indeed the suggestion of an
acceleration in the rate of eGFR decline after initiation
of HCT, from − 1.35 mL/min/1.73m2 per year to −
3.97 mL/minute/1.73m2 per year (Fig. 2). This finding of
a possible increased rate of eGFR decline after HCT initi-
ation should be interpreted with caution, as evidence for
the possible deleterious effects of (thiazide) diuretics on
ADPKD disease progression is largely lacking. There is
one study that compared treatment with ACE-inhibitors
and diuretics in hypertensive ADPKD-patients [20]. In this
small, non-randomized trial, treatment with diuretics was
associated with significantly steeper rate of decline in
creatinine clearance during 5 years of follow-up, that may
point to a deleterious effects of diuretics.
Evidence regarding the combination of HCT with
tolvaptan is equally scarce. In the TEMPO trials and the
REPRISE trial, concomitant diuretic use was an exclu-
sion criterion [4, 5, 21]. To our knowledge, only one
study specifically investigated the effects of concomitant
HCT and tolvaptan use. In that study co-administration
Fig. 2 eGFR over time. Tolvaptan has a hemodynamic effect on eGFR (as calculated by the CKD-EPI formula) that occurs acutely after start of the
drug, that is reversible after stopping (as can be seen in 2011). After hydrochlorothiazide (HCT) was started in 2015 the rate of eGFR decline
seems steeper. Separate trend lines are shown for eGFR decline on tolvaptan monotherapy and for eGFR decline on tolvaptan-HCT
combination therapy
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of a single dose of 30 mg tolvaptan and 100 mg HCT
was compared to administration of a single dose of
30 mg tolvaptan alone in twelve healthy subjects [22].
No significant effect of adding HCT to tolvaptan treat-
ment on vasopressin concentration was noted. In con-
trast to our findings, polyuria was also not affected by
concomitant HCT and tolvaptan use. However, to fully
disclose the potential antidiuretic effect of HCT, volume
contraction and therefore multiple dosing will be neces-
sary. The effects of low-dose HCT concomitant to tol-
vaptan on vasopressin concentration require additional
research before firm conclusions can be drawn.
A strength of this report is that at the moment HCT
was initiated neither the patient, nor the physician were
aware of possible effects of HCT usage on urine produc-
tion, limiting the risk of bias. Urine volumes in this
patient were only checked retrospectively.
Conclusion
Our case suggests that prescription of HCT during
tolvaptan use in ADPKD may lead to less polyuria. This
improvement in tolerability, however, was accompanied
by a rise in copeptin and a possibly accelerated rate of
eGFR decline. Furthermore, there theoretically may be
risks with respect to hydration status and serum electro-
lyte concentrations during combined tolvaptan-HCT
use, although we found no indications for this in our pa-
tient. Taken together these findings indicate that, until
further research suggests otherwise, tolvaptan-HCT
co-prescription should only be used with great scrutiny.
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